Monocarboxylate transporters as targets and mediators in cancer therapy response

Histology and Histopathology

Volumn 29, Issue 12, 2014, Pages 1511-1524

  Baltazar, Fátima ^a,b   Pinheiro, C ^a,b,c,d   Morais Santos, F ^a,b   Azevedo Silva, J ^b   Queiros O ^b,e   Preto, A ^b   Casal, M ^b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Barretos School of Health Sciences   (Brazil)

^d BARRETOS CANCER HOSPITAL   (Brazil)

^e INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Cancer therapy; Glycolysis; Molecular targets; Monocarboxylate transporters

Indexed keywords

MONOCARBOXYLATE TRANSPORTER;

ANIMAL; DRUG RESISTANCE; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASMS;

EID: 84907828807     PISSN: 02133911     EISSN: 16995848     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Asada K., Miyamoto K., Fukutomi T., Tsuda H., Yagi Y., Wakazono K., Oishi S., Fukui H., Sugimura T. and Ushijima T. (2003). Reduced expression of gna11 and silencing of mct1 in human breast cancers. Oncology 64, 380-388.
2. Baba M., Inoue M., Itoh K. and Nishizawa Y. (2008). Blocking cd147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun. 374, 111- 116.
3. Babu E., Ramachandran S., CoothanKandaswamy V., Elangovan S., Prasad P.D., Ganapathy V. and Thangaraju M. (2011). Role of slc5a8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene 30, 4026-4037.
4. Ben-Horin H., Tassini M., Vivi A., Navon G. and Kaplan O. (1995). Mechanism of action of the antineoplastic drug lonidamine: 31p and 13c nuclear magnetic resonance studies. Cancer Res. 55, 2814- 2821.
5. Ben-Yoseph O., Lyons J.C., Song C.W. and Ross B.D. (1998). Mechanism of action of lonidamine in the 9l brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol. 36, 149-157.
6. Bergersen L., Johannsson E., Veruki M.L., Nagelhus E.A., Halestrap A., Sejersted O.M. and Ottersen O.P. (1999). Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience 90, 319-331.
7. Bhardwaj V., Rizvi N., Lai M.B., Lai J.C. and Bhushan A. (2010). Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res. 30, 743- 749.
8. Birsoy K., Wang T., Possemato R., Yilmaz O.H., Koch C.E., Chen W.W., Hutchins A.W., Gultekin Y., Peterson T.R., Carette J.E., Brummelkamp T.R., Clish C.B. and Sabatini D.M. (2013). Mct1- mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104-108.
9. Biswas C., Zhang Y., DeCastro R., Guo H., Nakamura T., Kataoka H. and Nabeshima K. (1995). The human tumor cell-derived collagenase stimulatory factor (renamed emmprin) is a member of the immunoglobulin superfamily. Cancer Res. 55, 434-439.
10. Bonen A., Tonouchi M., Miskovic D., Heddle C., Heikkila J.J. and Halestrap A.P. (2000). Isoform-specific regulation of the lactate transporters mct1 and mct4 by contractile activity. Am. J. Physiol. Endocrinol. Metab. 279, E1131-1138.
11. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B. and Michelakis E.D. (2007). A mitochondria-k+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51.
12. Broer S., Broer A., Schneider H.P., Stegen C., Halestrap A.P. and Deitmer J.W. (1999). Characterization of the high-affinity monocarboxylate transporter mct2 in xenopus laevis oocytes. Biochemistry 341 ( Pt 3), 529-535.
13. Busk M., Walenta S., Mueller-Klieser W., Steiniche T., Jakobsen S., Horsman M.R. and Overgaard J. (2011). Inhibition of tumor lactate oxidation: Consequences for the tumor microenvironment. Radiother. Oncol. 99, 404-411.
14. Cardaci S., Rizza S., Filomeni G., Bernardini R., Bertocchi F., Mattei M., Paci M., Rotilio G. and Ciriolo M.R. (2012). Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res. 72, 4526-4536.
15. Chen Z., Zhang H., Lu W. and Huang P. (2009). Role of mitochondriaassociated hexokinase ii in cancer cell death induced by 3- bromopyruvate. Biochim. Biophys. Acta 1787, 553-560.
16. Chen C., Zhou J. and Ji C. (2010). Quercetin: A potential drug to reverse multidrug resistance. Life Sci. 87, 333-338.
17. Colen C.B., Seraji-Bozorgzad N., Marples B., Galloway M.P., Sloan A.E. and Mathupala S.P. (2006). Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: An in vitro study. Neurosurgery 59, 1313-1323; discussion 1323-1314.
18. Colen C.B., Shen Y., Ghoddoussi F., Yu P., Francis T.B., Koch B.J., Monterey M.D., Galloway M.P., Sloan A.E. and Mathupala S.P. (2011). Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: An in vivo study. Neoplasia 13, 620-632.
19. Cooper R.H., Randle P.J. and Denton R.M. (1974). Regulation of heart muscle pyruvate dehydrogenase kinase. Biochem. J. 143, 625-641.
20. Davidescu M., Sciaccaluga M., Macchioni L., Angelini R., Lopalco P., Rambotti M.G., Roberti R., Corcelli A., Castigli E. and Corazzi L. (2012). Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in gl15 glioblastoma cells. J. Bioenerg. Biomembr. 44, 51-60.
21. de Oliveira A.T., Pinheiro C., Longatto-Filho A., Brito M.J., Martinho O., Matos D., Carvalho A.L., Vazquez V.L., Silva T.B., Scapulatempo C., Saad S.S., Reis R.M. and Baltazar F. (2012). Co-expression of monocarboxylate transporter 1 (mct1) and its chaperone (cd147) is associated with low survival in patients with gastrointestinal stromal tumors (gists). J. Bioenerg. Biomembr. 44, 171-178.
22. DeBerardinis R.J., Lum J.J., Hatzivassiliou G. and Thompson C.B. (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20.
23. Deora A.A., Philp N., Hu J., Bok D. and Rodriguez-Boulan E. (2005). Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone cd147 in kidney and retinal epithelia. Proc. Natl. Acad. Sci. USA 102, 16245-16250.
24. Deuticke B. (1982). Monocarboxylate transport in erythrocytes. J. Membr. Biol. 70, 89-103.
25. Dhar S. and Lippard S.J. (2009). Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc. Natl. Acad. Sci. USA 106, 22199-22204.
26. Dimmer K.S., Friedrich B., Lang F., Deitmer J.W. and Broer S. (2000). The low-affinity monocarboxylate transporter mct4 is adapted to the export of lactate in highly glycolytic cells. Biochem. J. 350, 219-227.
27. Dhup S., Dadhich R.K., Porporato P.E. and Sonveaux P. (2012). Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Des. 18, 1319-1330.
28. El Sayed S.M., El-Magd R.M., Shishido Y., Chung S.P., Diem T.H., Sakai T., Watanabe H., Kagami S. and Fukui K. (2012). 3- bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J. Bioenerg. Biomembr. 44, 61-79.
29. Fahim F.A., Esmat A.Y., Mady E.A. and Ibrahim E.K. (2003). Antitumor activities of iodoacetate and dimethylsulphoxide against solid ehrlich carcinoma growth in mice. Biol. Res. 36, 253-262.
30. Fang J., Quinones Q.J., Holman T.L., Morowitz M.J., Wang Q., Zhao H., Sivo F., Maris J.M. and Wahl M.L. (2006). The h+-linked monocarboxylate transporter (mct1/slc16a1): A potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol. 70, 2108-2115.
31. Fishbein W.N., Foellmer J.W., Davis J.I., Fishbein T.M. and Armbrustmacher P. (1988). Clinical assay of the human erythrocyte lactate transporter. I. Principles, procedure, and validation. Biochem. Med. Metab. Biol. 39, 338-350.
32. Fishbein W.N., Merezhinskaya N. and Foellmer J.W. (2002). Relative distribution of three major lactate transporters in frozen human tissues and their localization in unfixed skeletal muscle. Muscle Nerve 26, 101-112.
33. Floridi A., Paggi M.G., D'Atri S., De Martino C., Marcante M.L., Silvestrini B. and Caputo A. (1981). Effect of lonidamine on the energy metabolism of ehrlich ascites tumor cells. Cancer Res. 41, 4661-4666.
34. Friesema E.C., Ganguly S., Abdalla A., Manning Fox J.E., Halestrap A.P. and Visser T.J. (2003). Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J. Biol. Chem. 278, 40128-40135.
35. Friesema E.C., Jansen J., Jachtenberg J.W., Visser W.E., Kester M.H. and Visser T.J. (2008). Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol. Endocrinol. 22, 1357-1369.
36. Froberg M.K., Gerhart D.Z., Enerson B.E., Manivel C., Guzman-Paz M., Seacotte N. and Drewes L.R. (2001). Expression of monocarboxylate transporter mct1 in normal and neoplastic human cns tissues. Neuroreport 12, 761-765.
37. Froberg M.K., Gerhart, D.Z., Enerson, B.E., Manivel, C., Guzman-Paz, M., Seacotte, N., and Drewes, L.R. (2001). Expression of monocarboxylate transporters mct1 and mct2 in normal and neoplastic human cns tissues. Neuroreport 12, 761-765.
38. Gallagher S.M., Castorino J.J., Wang D. and Philp N.J. (2007). Monocarboxylate transporter 4 regulates maturation and trafficking of cd147 to the plasma membrane in the metastatic breast cancer cell line mda-mb-231. Cancer Res. 67, 4182-4189.
39. Gallagher S.M., Castorino J.J. and Philp N.J. (2009). Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration. Am. J. Physiol. Cell. Physiol. 296, C414-421.
40. Ganapathy V., Gopal E., Miyauchi S. and Prasad P.D. (2005). Biological functions of slc5a8, a candidate tumour suppressor. Biochem. Soc. Trans. 33, 237-240.
41. Ganapathy V., Thangaraju M., Gopal E., Martin P.M., Itagaki S., Miyauchi S. and Prasad P.D. (2008). Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10, 193-199.
42. Ganapathy-Kanniappan S., Vali M., Kunjithapatham R., Buijs M., Syed L.H., Rao P.P., Ota S., Kwak B.K., Loffroy R. and Geschwind J.F. (2010). 3-bromopyruvate: A new targeted antiglycolytic agent and a promise for cancer therapy. Curr. Pharm. Biotechnol. 11, 510-517.
43. Ganapathy-Kanniappan S., Kunjithapatham R. and Geschwind J.F. (2013). Anticancer efficacy of the metabolic blocker 3- bromopyruvate: Specific molecular targeting. Anticancer Res. 33, 13-20.
44. Garcia C.K., Brown M.S., Pathak R.K. and Goldstein J.L. (1995). Cdna cloning of mct2, a second monocarboxylate transporter expressed in different cells than mct1. J. Biol. Chem. 270, 1843-1849.
45. Gatenby R.A. and Gillies R.J. (2004). Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899.
46. Gatenby R.A. and Gillies R.J. (2007). Glycolysis in cancer: A potential target for therapy. Int. J. Biochem. Cell Biol. 39, 1358-1366.
47. Gatenby R.A., Smallbone K., Maini P.K., Rose F., Averill J., Nagle R.B., Worrall L. and Gillies R.J. (2007). Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br. J. Cancer 97, 646-653.
48. Gillies R.J. and Gatenby R.A. (2007). Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis? J. Bioenerg. Biomembr. 39, 251-257.
49. Globocan (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx. Accessed April 9, 2014.
50. Granchi C. and Minutolo F. (2012). Anticancer agents that counteract tumor glycolysis. Chem. Med. Chem. 7, 1318-1350.
51. Grollman E.F., Philp N.J., McPhie P., Ward R.D. and Sauer B. (2000). Determination of transport kinetics of chick mct3 monocarboxylate transporter from retinal pigment epithelium by expression in genetically modified yeast. Biochemistry 39, 9351-9357.
52. Guo C., Liu S. and Sun M.Z. (2013). Novel insight into the role of gapdh playing in tumor. Clin. Transl. Oncol. 15, 167-172.
53. Halestrap A.P. (2012). The monocarboxylate transporter family-- structure and functional characterization. IUBMB Life 64, 1-9.
54. Halestrap A.P. (2013). The slc16 gene family - structure, role and regulation in health and disease. Mol. Aspects Med. 34, 337-349.
55. Halestrap A.P. and Price N.T. (1999). The proton-linked monocarboxylate transporter (mct) family: Structure, function and regulation. Biochem. J. 343 Pt 2, 281-299.
56. Halestrap A.P. and Meredith D. (2004). The slc16 gene family-from monocarboxylate transporters (mcts) to aromatic amino acid transporters and beyond. Pflugers Arch. 447, 619-628.
57. Halestrap A.P. and Wilson M.C. (2012). The monocarboxylate transporter family--role and regulation. IUBMB Life 64, 109-119.
58. Hanahan D. and Weinberg R.A. (2011). The hallmarks of cancer: The next generation. Cell 144, 636-674.
59. Hao J., Chen H., Madigan M.C., Cozzi P.J., Beretov J., Xiao W., Delprado W.J., Russell P.J. and Li Y. (2010). Co-expression of cd147 (emmprin), cd44v3-10, mdr1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br. J. Cancer 103, 1008-1018.
60. Harris J.L. and Walter M. (1976). Glyceraldehyde-3-phosphate dehydrogenase. In: The enzymes. Boyer P.D. (ed). Academic Press. New York. pp 1-49.
61. Heshe D., Hoogestraat S., Brauckmann C., Karst U., Boos J. and Lanvers-Kaminsky C. (2011). Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother. Pharmacol. 67, 647-655.
62. Higashimura Y., Nakajima Y., Yamaji R., Harada N., Shibasaki F., Nakano Y. and Inui H. (2011). Up-regulation of glyceraldehyde-3- phosphate dehydrogenase gene expression by hif-1 activity depending on sp1 in hypoxic breast cancer cells. Arch. Biochem. Biophys. 509, 1-8.
63. Huang R.P., Ozawa M., Kadomatsu K. and Muramatsu T. (1990). Developmentally regulated expression of embigin, a member of the immunoglobulin superfamily found in embryonal carcinoma cells. Differentiation 45, 76-83.
64. Icard P., Zhang X.D., Lemoisson E., Louis M.H., Allouche S., Lincet H. and Poulain L. (2012). Experimental results using 3-bromopyruvate in mesothelioma: In vitro and in vivo studies. J. Bioenerg. Biomembr. 44, 81-90.
65. Jackson V.N. and Halestrap A.P. (1996). The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular ph indicator, 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein. J. Biol. Chem. 271, 861-868.
66. Jones N.P. and Schulze A. (2012). Targeting cancer metabolism-- aiming at a tumour's sweet-spot. Drug Discov. Today 17, 232-241.
67. Juel C. (1997). Lactate-proton cotransport in skeletal muscle. Physiol. Rev. 77, 321-358.
68. Kay H.H., Zhu S. and Tsoi S. (2007). Hypoxia and lactate production in trophoblast cells. Placenta 28, 854-860.
69. Kim D.K., Kanai Y., Chairoungdua A., Matsuo H., Cha S.H. and Endou H. (2001). Expression cloning of a na+-independent aromatic amino acid transporter with structural similarity to h+/monocarboxylate transporters. J. Biol. Chem. 276, 17221-17228.
70. Kim J.S., Ahn K.J., Kim J.A., Kim H.M., Lee J.D., Lee J.M., Kim S.J. and Park J.H. (2008). Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: Ros-mediated cell death by 3-brpa. J. Bioenerg. Biomembr. 40, 607-618.
71. Kim H.S., Masko E.M., Poulton S.L., Kennedy K.M., Pizzo S.V., Dewhirst M.W. and Freedland S.J. (2012). Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 110, 1062-1069.
72. Kirk P., Wilson M.C., Heddle C., Brown M.H., Barclay A.N. and Halestrap A.P. (2000). Cd147 is tightly associated with lactate transporters mct1 and mct4 and facilitates their cell surface expression. EMBO J. 19, 3896-3904.
73. Kloeckener-Gruissem B., Vandekerckhove K., Nurnberg G., Neidhardt J., Zeitz C., Nurnberg P., Schipper I. and Berger W. (2008). Mutation of solute carrier slc16a12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria. Am. J. Hum. Genet. 82, 772-779.
74. Knoechel T.R., Tucker A.D., Robinson C.M., Phillips C., Taylor W., Bungay P.J., Kasten S.A., Roche T.E. and Brown D.G. (2006). Regulatory roles of the n-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry 45, 402-415.
75. Ko Y.H., Pedersen P.L. and Geschwind J.F. (2001). Glucose catabolism in the rabbit vx2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett. 173, 83-91.
76. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J. and Pedersen P.L. (2004). Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 324, 269-275.
77. Ko Y.H., Verhoeven H.A., Lee M.J., Corbin D.J., Vogl T.J. and Pedersen P.L. (2012). A translational study "Case report" On the small molecule "Energy blocker" 3-bromopyruvate (3bp) as a potent anticancer agent: From bench side to bedside. J. Bioenerg. Biomembr. 44, 163-170.
78. Kobayashi M., Otsuka Y., Itagaki S., Hirano T. and Iseki K. (2006). Inhibitory effects of statins on human monocarboxylate transporter 4. Int. J. Pharm. 317, 19-25.
79. Kondoh H., Lleonart M.E., Bernard D. and Gil J. (2007). Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol. Histopathol. 22, 85-90.
80. Koukourakis M.I., Giatromanolaki A., Harris A.L. and Sivridis E. (2006). Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-associated stroma. Cancer Res. 66, 632-637.
81. Koukourakis M.I., Giatromanolaki A., Bougioukas G. and Sivridis E. (2007). Lung cancer: A comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol. Ther. 6, 1476-1479.
82. Kroemer G. and Pouyssegur J. (2008). Tumor cell metabolism: Cancer's achilles' heel. Cancer Cell 13, 472-482.
83. Ladanyi M., Antonescu C.R., Drobnjak M., Baren A., Lui M.Y., Golde D.W. and Cordon-Cardo C. (2002). The precrystalline cytoplasmic granules of alveolar soft Part sarcoma contain monocarboxylate transporter 1 and cd147. Am. J. Pathol. 160, 1215-1221.
84. Lambert D.W., Wood I.S., Ellis A. and Shirazi-Beechey S.P. (2002). Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br. J. Cancer 86, 1262-1269.
85. Le Floch R., Chiche J., Marchiq I., Naiken T., Ilc K., Murray C.M., Critchlow S.E., Roux D., Simon M.P. and Pouyssegur J. (2011). Cd147 subunit of lactate/h+ symporters mct1 and hypoxia-inducible mct4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. USA 108, 16663-16668.
86. Lin R.Y., Vera J.C., Chaganti R.S. and Golde D.W. (1998). Human monocarboxylate transporter 2 (mct2) is a high affinity pyruvate transporter. J. Biol. Chem. 273, 28959-28965.
87. Makuc J., Cappellaro C. and Boles E. (2004). Co-expression of a mammalian accessory trafficking protein enables functional expression of the rat mct1 monocarboxylate transporter in saccharomyces cerevisiae. FEMS Yeast Res. 4, 795-801.
88. Manning Fox J.E., Meredith D. and Halestrap A.P. (2000). Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J. Physiol. 529 Pt 2, 285-293.
89. Martinez-Zaguilan R., Seftor E.A., Seftor R.E., Chu Y.W., Gillies R.J. and Hendrix M.J. (1996). Acidic ph enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis. 14, 176-186.
90. Mathupala S.P., Parajuli P. and Sloan A.E. (2004). Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: An in vitro study. Neurosurgery 55, 1410-1419; discussion 1419.
91. Matsumoto S., Saito K., Yasui H., Morris H.D., Munasinghe J.P., Lizak M., Merkle H., Ardenkjaer-Larsen J.H., Choudhuri R., Devasahayam N., Subramanian S., Koretsky A.P., Mitchell J.B. and Krishna M.C. (2013). Epr oxygen imaging and hyperpolarized 13c mri of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn. Reson. Med. 69, 1443-1450.
92. McClelland G.B. and Brooks G.A. (2002). Changes in mct 1, mct 4, and ldh expression are tissue specific in rats after long-term hypobaric hypoxia. J. Appl. Physiol. 92, 1573-1584.
93. Miranda-Goncalves V., Honavar M., Pinheiro C., Martinho O., Pires M.M., Cordeiro M., Bebiano G., Costa P., Palmeirim I., Reis R.M. and Baltazar F. (2013). Monocarboxylate transporters (mcts) in gliomas: Expression and exploitation as therapeutic targets. Neuro. Oncol. 15, 172-188.
94. Morais-Santos F., Miranda-Goncalves V., Pinheiro S., Vieira A.F., Paredes J., Schmitt F.C., Baltazar F. and Pinheiro C. (2014). Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr. Relat. Cancer. 21, 27-38.
95. Moreno-Sanchez R., Rodriguez-Enriquez S., Marin-Hernandez A. and Saavedra E. (2007). Energy metabolism in tumor cells. FEBS J. 274, 1393-1418.
96. Murakami A., Ashida H. and Terao J. (2008). Multitargeted cancer prevention by quercetin. Cancer Lett. 269, 315-325.
97. Nakano A., Miki H., Nakamura S., Harada T., Oda A., Amou H., Fujii S., Kagawa K., Takeuchi K., Ozaki S., Matsumoto T. and Abe M. (2012). Up-regulation of hexokinaseii in myeloma cells: Targeting myeloma cells with 3-bromopyruvate. J. Bioenerg. Biomembr. 44, 31-38.
98. Ord J.J., Streeter E.H., Roberts I.S., Cranston D. and Harris A.L. (2005). Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br. J. Cancer 93, 346-354.
99. Ovens M.J., Davies A.J., Wilson M.C., Murray C.M. and Halestrap A.P. (2010). Ar-c155858 is a potent inhibitor of monocarboxylate transporters mct1 and mct2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 425, 523-530.
100. Pao S.S., Paulsen I.T. and Saier M.H., Jr. (1998). Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 62, 1-34.
101. Papandreou I., Goliasova T. and Denko N.C. (2011). Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? Int. J. Cancer 128, 1001-1008.
102. Park H.J., Lyons J.C., Ohtsubo T. and Song C.W. (1999). Acidic environment causes apoptosis by increasing caspase activity. Br. J. Cancer 80, 1892-1897.
103. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., Casimiro M.C., Wang C., Fortina P., Addya S., Pestell R.G., Martinez-Outschoorn U.E., Sotgia F. and Lisanti M.P. (2009). The reverse warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984-4001.
104. Pereira da Silva A.P., El-Bacha T., Kyaw N., dos Santos R.S., da-Silva W.S., Almeida F.C., Da Poian A.T. and Galina A. (2009). Inhibition of energy-producing pathways of hepg2 cells by 3-bromopyruvate. Biochem. J. 417, 717-726.
105. Perez de Heredia F., Wood I.S. and Trayhurn P. (2010). Hypoxia stimulates lactate release and modulates monocarboxylate transporter (mct1, mct2, and mct4) expression in human adipocytes. Pflugers Arch. 459, 509-518.
106. Pertega-Gomes N., Vizcaino J.R., Gouveia C., Jeronimo C., Henrique R.M., Lopes C. and Baltazar F. (2013). Monocarboxylate transporter 2 (mct2) as putative biomarker in prostate cancer. Prostate 73, 763- 769.
107. Pertega-Gomes N., Vizcaino J.R., Miranda-Goncalves V., Pinheiro C., Silva J., Pereira H., Monteiro P., Henrique R.M., Reis R.M., Lopes C. and Baltazar F. (2011). Monocarboxylate transporter 4 (mct4) and cd147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11, 312.
108. Philp N.J., Yoon H. and Grollman E.F. (1998). Monocarboxylate transporter mct1 is located in the apical membrane and mct3 in the basal membrane of rat rpe. Am. J. Physiol. 274, R1824-1828.
109. Philp N.J., Ochrietor J.D., Rudoy C., Muramatsu T. and Linser P.J. (2003). Loss of mct1, mct3, and mct4 expression in the retinal pigment epithelium and neural retina of the 5a11/basigin-null mouse. Invest. Ophthalmol. Visual Sci. 44, 1305-1311.
110. Pierre K., Magistretti P.J. and Pellerin L. (2002). Mct2 is a major neuronal monocarboxylate transporter in the adult mouse brain. J. Cereb. Blood Flow Metab. 22, 586-595.
111. Pinheiro C., Longatto-Filho A., Scapulatempo C., Ferreira L., Martins S., Pellerin L., Rodrigues M., Alves V.A., Schmitt F. and Baltazar F. (2008a). Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arc. 452, 139-146.
112. Pinheiro C., Longatto-Filho A., Ferreira L., Pereira S.M., Etlinger D., Moreira M.A., Jube L.F., Queiroz G.S., Schmitt F. and Baltazar F. (2008b). Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int. J. Gynecol. Pathol. 27, 568-574.
113. Pinheiro C., Longatto-Filho A., Simoes K., Jacob C.E., Bresciani C.J., Zilberstein B., Cecconello I., Alves V.A., Schmitt F. and Baltazar F. (2009). The prognostic value of cd147/emmprin is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur. J. Cancer 45, 2418-2424.
114. Pinheiro C., Albergaria A., Paredes J., Sousa B., Dufloth R., Vieira D., Schmitt F. and Baltazar F. (2010). Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56, 860- 867.
115. Pinheiro C., Longatto-Filho A., Azevedo-Silva J., Casal M., Schmitt F.C. and Baltazar F. (2012a). Role of monocarboxylate transporters in human cancers: State of the art. J. Bioenerg. Biomembr. 44, 127- 139.
116. Porporato P.E., Dhup S., Dadhich R.K., Copetti T. and Sonveaux P. (2011). Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front. Pharmacol. 2, 49.
117. Price N.T., Jackson V.N. and Halestrap A.P. (1998). Cloning and sequencing of four new mammalian monocarboxylate transporter (mct) homologues confirms the existence of a transporter family with an ancient past. Biochem. J. 329 ( Pt 2), 321-328.
118. Queiros O., Preto A., Pacheco A., Pinheiro C., Azevedo-Silva J., Moreira R., Pedro M., Ko Y.H., Pedersen P.L., Baltazar F. and Casal M. (2012). Butyrate activates the monocarboxylate transporter mct4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J. Bioenerg. Biomembr. 44, 141-153.
119. Rae C., Fekete A.D., Kashem M.A., Nasrallah F.A. and Broer S. (2012). Metabolism, compartmentation, transport and production of acetate in the cortical brain tissue slice. Neurochem. Res. 37, 2541-2553.
120. Ritzhaupt A., Wood I.S., Ellis A., Hosie K.B. and Shirazi-Beechey S.P. (1998). Identification of a monocarboxylate transporter isoform type 1 (mct1) on the luminal membrane of human and pig colon. Biochem. Soc. Trans. 26, S120.
121. Rodriguez-Enriquez S., Marin-Hernandez A., Gallardo-Perez J.C. and Moreno-Sanchez R. (2009). Kinetics of transport and phosphorylation of glucose in cancer cells. J. Cell. Physiol. 221, 552-559.
122. Rofstad E.K., Mathiesen B., Kindem K. and Galappathi K. (2006). Acidic extracellular ph promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 66, 6699-6707.
123. Sanchez-Arago M. and Cuezva J.M. (2011). The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J. Transl. Med. 9, 19.
124. Schneiderhan W., Scheler M., Holzmann K.H., Marx M., Gschwend J.E., Bucholz M., Gress T.M., Seufferlein T., Adler G. and Oswald F. (2009). Cd147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58, 1391-1398.
125. Slomiany M.G., Grass G.D., Robertson A.D., Yang X.Y., Maria B.L., Beeson C. and Toole B.P. (2009). Hyaluronan, cd44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res. 69, 1293-1301.
126. Smallbone K., Gavaghan D.J., Gatenby R.A. and Maini P.K. (2005). The role of acidity in solid tumour growth and invasion. J. Theor. Biol. 235, 476-484.
127. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., DiePart C., Jordan B.F., Kelley M.J., Gallez B., Wahl M.L., Feron O. and Dewhirst M.W. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942.
128. Stacpoole P.W., Lorenz A.C., Thomas R.G. and Harman E.M. (1988). Dichloroacetate in the treatment of lactic acidosis. Ann. Intern. Med. 108, 58-63.
129. Stockwin L.H., Yu S.X., Borgel S., Hancock C., Wolfe T.L., Phillips L.R., Hollingshead M.G. and Newton D.L. (2010). Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int. J. Cancer 127, 2510-2519.
130. Su J., Chen X. and Kanekura T. (2009). A cd147-targeting sirna inhibits the proliferation, invasiveness, and vegf production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 273, 140-147.
131. Tang Z., Yuan S., Hu Y., Zhang H., Wu W., Zeng Z., Yang J., Yun J., Xu R. and Huang P. (2012). Over-expression of gapdh in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J. Bioenerg. Biomembr. 44, 117-125.
132. Tennant D.A., Duran R.V. and Gottlieb E. (2010). Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277.
133. Thangaraju M., Karunakaran S.K., Itagaki S., Gopal E., Elangovan S., Prasad P.D. and Ganapathy V. (2009). Transport by slc5a8 with subsequent inhibition of histone deacetylase 1 (hdac1) and hdac3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115, 4655-4666.
134. Ullah M.S., Davies A.J. and Halestrap A.P. (2006). The plasma membrane lactate transporter mct4, but not mct1, is up-regulated by hypoxia through a hif-1alpha-dependent mechanism. J. Biol. Chem. 281, 9030-9037.
135. Vander Heiden M.G. (2011). Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684.
136. Vegran F., Boidot R., Michiels C., Sonveaux P. and Feron O. (2011). Lactate influx through the endothelial cell monocarboxylate transporter mct1 supports an nf-kappab/il-8 pathway that drives tumor angiogenesis. Cancer Res. 71, 2550-2560.
137. Wahl M.L., Owen J.A., Burd R., Herlands R.A., Nogami S.S., Rodeck U., Berd D., Leeper D.B. and Owen C.S. (2002). Regulation of intracellular ph in human melanoma: Potential therapeutic implications. Mol. Cancer Ther. 1, 617-628.
138. Wang Q. and Morris M.E. (2007). Flavonoids modulate monocarboxylate transporter-1-mediated transport of gammahydroxybutyrate in vitro and in vivo. Drug Metab. Dispos. 35, 201- 208.
139. Wang T., Marquardt C. and Foker J. (1976). Aerobic glycolysis during lymphocyte proliferation. Nature 261, 702-705.
140. Warburg O. (1956). On the origin of cancer cells. Science 123, 309-314.
141. Whitehouse S., Cooper R.H. and Randle P.J. (1974). Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem. J. 141, 761-774.
142. Williams A.C., Collard T.J. and Paraskeva C. (1999). An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: Implications for clonal selection during colorectal carcinogenesis. Oncogene 18, 3199- 3204.
143. Wilson M.C., Jackson V.N., Heddle C., Price N.T., Pilegaard H., Juel C., Bonen A., Montgomery I., Hutter O.F. and Halestrap A.P. (1998). Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform mct3. J. Biol. Chem. 273, 15920-15926.
144. Wilson M.C., Meredith D. and Halestrap A.P. (2002). Fluorescence resonance energy transfer studies on the interaction between the lactate transporter mct1 and cd147 provide information on the topology and stoichiometry of the complex in situ. J. Biol. Chem. 277, 3666-3672.
145. Wilson M.C., Meredith D., Fox J.E., Manoharan C., Davies A.J. and Halestrap A.P. (2005). Basigin (cd147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: The ancillary protein for the insensitive mct2 is embigin (gp70). J. Biol. Chem. 280, 27213-27221.
146. Wolf A., Agnihotri S., Micallef J., Mukherjee J., Sabha N., Cairns R., Hawkins C. and Guha A. (2011). Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 208, 313-326.
147. Yoon H., Fanelli A., Grollman E.F. and Philp N.J. (1997). Identification of a unique monocarboxylate transporter (mct3) in retinal pigment epithelium. Biochem. Biophys. Res. Commun. 234, 90-94.
148. Zhang F., Vannucci S.J., Philp N.J. and Simpson I.A. (2005). Monocarboxylate transporter expression in the spontaneous hypertensive rat: Effect of stroke. J. Neurosci. Res. 79, 139- 145.
149. Zhao C., Wilson M.C., Schuit F., Halestrap A.P. and Rutter G.A. (2001). Expression and distribution of lactate/monocarboxylate transporter isoforms in pancreatic islets and the exocrine pancreas. Diabetes 50, 361-366.
150. Zuercher J., Neidhardt J., Magyar I., Labs S., Moore A.T., Tanner F.C., Waseem N., Schorderet D.F., Munier F.L., Bhattacharya S., Berger W. and Kloeckener-Gruissem B. (2010). Alterations of the 5'untranslated region of slc16a12 lead to age-related cataract. Invest. Ophthalmol. Vis. Sci. 51, 3354-3361.